Status:
COMPLETED
A Study to Evaluate EDP 938 Regimens in Children With RSV
Lead Sponsor:
Enanta Pharmaceuticals, Inc
Conditions:
Respiratory Syncytial Virus (RSV)
Eligibility:
All Genders
28-36 years
Phase:
PHASE2
Brief Summary
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Detailed Description
This is a randomized, double-blind, dose ranging, placebo-controlled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 36 months, assessi...
Eligibility Criteria
Inclusion
- Male or female who is either ≥6 months to ≤36 months (for Age Group 1) or ≥28 days to \<6 months (for Age Group 2), defined at the time of randomization. Subjects in Age Group 2 must have been born ≥29 weeks of gestation to be eligible.
- Subjects diagnosed with RSV infection
- Subjects with signs of an acute respiratory illness with onset ≤7 days for Part 1 and ≤5 days for Part 2 before the time of signing the ICF
- In the Investigator's opinion, the subject's caregiver understands and is able to comply with protocol requirements, instructions, and protocol-stated restrictions, and the subject is likely to complete the study as planned
Exclusion
- Use of or anticipated need for invasive mechanical ventilation, cardiopulmonary bypass, hemodialysis, or extracorporeal membrane oxygenation; or subjects who are not expected to survive the current illness
- Underlying immune deficiency, (e.g., from confirmed human immunodeficiency virus infection or use of an immunosuppressive medication except immunoglobulin A deficiency)
- Receipt of (within 12 months before Screening) or on a waiting list for a bone marrow, stem cell, or solid organ transplant, or who received radiation or chemotherapy (within 12 months before screening)
- Receiving chronic oxygen therapy at home before admission
- Subjects whose mother received an investigational RSV vaccination while pregnant with the subject if they were born at term (≥37 weeks of gestation) and are less than 12 months of age
- In Part 2, subjects dosed with an investigational or approved medication that is intended to prevent or treat RSV infection within the following times before the first dose of study drug: ribavirin 35 days; palivizumab 100 days; nirsevimab 350 days; other RSV-specific monoclonal antibody 5 half-lives of the specific antibody; RSV vaccines 12 months.
Key Trial Info
Start Date :
April 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2024
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04816721
Start Date
April 26 2022
End Date
August 19 2024
Last Update
July 28 2025
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Care Miller Children's and Women's Hospital
Long Beach, California, United States, 90806
2
University of California Los Angeles (UCLA)
Los Angeles, California, United States, 90095
3
University of California Davis
Sacramento, California, United States, 95817
4
Nemours Children's Hospital
Orlando, Florida, United States, 32827